Press release – No. 24 / 2026 Zealand Pharma announces EU approval of ZeydovioTM (glepaglutide) for the treatment of short bowel syndrome The approval marks the first major advancement in short bowel syndrome treatment in Europe in more than a decadeZeydovioTM is the first and only ready-to-use GLP-2 therapy to receive regulatory approvalClinically evidenced efficacy paired with simple delivery, positions ZeydovioTM as a transformative therapy for people living with short bowel syndromeActive

TORONTO, ONTARIO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) today reported its financial and operating results for the third quarter ended September 30, 2026. All amounts in this press release are in U.S. dollars. Peter Puccetti, CEO & Chairman of the Board of COSCIENS remarked “While we are very pleased that Ceapro Inc. (“Ceapro”) continues to show materially improved revenues and profitability versus a year ago, the hi

CONSHOHOCKEN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: The fireside chats will be webcast live and can be accessed by visiting Madrigal’s Investor Relations Events page. Jefferies Global Healthcare Conference in LondonTuesday, Nov. 17, 2026 at 10:30 A.M. GMT (5:30 A.M. ET) 9th Annual Evercore Healthcare ConferenceTuesday, Dec. 1, 2026 at 8:2

Sanofi’s U.K. business is partnering up with British comic stalwart the Beano once again to help British schools boost awareness of Type 1 diabetes. The Beano first came out in the U.K. back in 1938 but became a real mainstay in British culture from the 1950s onward. It features the adventures of Dennis (formerly Dennis the Menace) and his dog Gnasher, as well as a whole host of characters with a uniquely British and often rebellious sense of humor. Sanofi UK, as part of its campaigning for Worl

The FDA has granted De Novo authorization for Virtuoso Surgical’s Virtuoso Endoscopy System . This is the first device in a new FDA classification for electromechanical surgical technologies aimed at endoluminal surgical procedures that use robotic instruments passed through an endoscope into the body. The system is authorized for en bloc resection of bladder lesions in adult patients to obtain tissue samples, including detrusor muscle, to assist in the diagnostic evaluation of bladder cancer. T

Windward Bio’s IPO has blown to exactly the spot the Swiss biotech had been aiming for, bringing in $225 million to fund a pair of respiratory drugs licensed from China. The Basel-based biotech hit its previously disclosed target of offering 10.3 million shares priced at $17 apiece. Windward has the potential to boost its $225 million in gross proceeds by around $26.2 million if underwriters take up their option to buy an additional 1.5 million shares at the same price. The stock is set to start

Regeneron has posted positive phase 2 data on baloncibart in postural orthostatic tachycardia syndrome (POTS), teeing the biotech up to start a potentially pivotal trial in the autonomic nervous system disorder in the first half of 2027. The heart rate of POTS patients increases abnormally when they get up from sitting or lying down. Some symptoms, such as palpitations and dizziness, happen when patients stand up and lessen when they sit or lie down. But POTS is also associated with ongoing symp

The IPO fortunes of a couple of clinical-stage biotechs diverged this week. Basel, Switzerland-based Windward Bio raised $175 million by pricing its IPO at $17 per share, while Boston-based Rezera postponed its planned public debut.Windward's offering priced at the midpoint of its proposed range of $16 to $18 per share, with the sale of around 10.3 million shares. The company also secured $50 million through a concurrent private placement to Sanofi, bringing expected gross proceeds to $225 milli

Intellia Therapeutics has presented additional evidence supporting the possible long-term potential of its experimental one-time CRISPR gene-editing therapy in hereditary angioedema (HAE).The findings for lonvoguran ziclumeran (lonvo-z), presented this week at the American College of Allergy, Asthma & Immunology (ACAAI) conference, include follow-up extending several years and may reassure physicians about the treatment's long-term durability (see – Physician Views In-Depth: New HAE prophylactic

AstraZeneca secured another US approval for Imfinzi (durvalumab) in bladder cancer on Friday, with the FDA clearing the PD-L1 inhibitor together with Pfizer and Astellas' Padcev (enfortumab vedotin) for adults with muscle-invasive bladder cancer (MIBC) who are ineligible for or have refused cisplatin-based chemotherapy.Specifically, the combo is indicated for use as neoadjuvant treatment, followed by Imfinzi monotherapy after radical cystectomy.The decision was based on the Phase III VOLGA trial